Alibaba Health Information Technology Limited
0241
Classement en actions
#3021
Alibaba Health Information Technology Limited, an investment holding company,... Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
Prix de l'action
$0.37403831
Capitalisation boursière
$6.05B
Changement (1 jour)
-4.14%
Changement (1 an)
-52.58%
Pays
HK
Échange Alibaba Health Information Technology Limited (0241)
Catégorie
Healthcare
Ratio P/E pour Alibaba Health Information Technology Limited (0241)
Ratio P/E au October 2026 TTM : 20.75
Selon les derniers rapports financiers et le cours de l'action de Alibaba Health Information Technology Limited, le ratio P/E actuel (TTM) est de 20.75. À la fin de l’année 2024, le P/E de l’entreprise était de 45.22.
Historique du ratio P/E pour Alibaba Health Information Technology Limited de 2004 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 20.75 | -57.88% |
| 2025 | 49.27 | 8.94% |
| 2024 | 45.22 | -63.88% |
| 2023 | 125.22 | -160.00% |
| 2022 | -208.70 | -129.63% |
| 2021 | 704.30 | -103.28% |
| 2020 | -21.44K | 2,011.22% |
| 2019 | -1.02K | 279.53% |
| 2018 | -267.62 | 119.20% |
| 2017 | -122.09 | -27.23% |
| 2016 | -167.77 | -67.80% |
| 2015 | -521.04 | -84.11% |
| 2014 | -3.28K | 8,214.77% |
| 2013 | -39.45 | -82.87% |
| 2012 | -230.32 | 46.15% |
| 2011 | -157.59 | 25.02% |
| 2010 | -126.05 | 3,538.25% |
| 2009 | -3.46 | -85.86% |
| 2008 | -24.49 | -46.94% |
| 2007 | -46.17 | -107.88% |
| 2006 | 586.00 | 28.82% |
| 2005 | 454.91 | -128.53% |
| 2004 | -1.59K | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 19.68 | -5.20% |
US
|
|
| 64.40 | 210.31% |
AU
|
|
| 44.30 | 113.46% |
US
|
|
| -47.78 | -330.20% |
US
|
|
| -123.90 | -696.99% |
US
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.